

A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS

(Alphabetisch nach Erstautor sortiert)

1. AGAZZI P, BIENCG, STAEDLER C, BIGLIO V, **GOBBI C**
Over 10 years follow-up of limbic encephalitis associated with anti-LG1 antibodies
J Neurol 2015;262(2):469-470. IF 3.377
2. **AMANN M***, **PAPADOPOULOU A***, **ANDELOVA M**, **MAGON S**, MUELLER-LENKE N, **NAEGELIN Y**, STIPPICH C, RADUE EW, BIERI O, **KAPPOS L**, **SPRENGER T** (* equally contributing 1st authors)
Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis
J Neurol 2015; 262(8):1909-17. IF: 3.377
3. **AMANN M**, **SPRENGER T**, **NAEGELIN Y**, REINHARDT J, KUSTER P, HIRSCH JG, **KAPPOS L**, **RADUE EW**, STIPPICH C, BIERI O
Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations
Neuroimage 2015; 108:87-94. IF: 6.357
4. ARVIN AM, WOLINSKY JS, **KAPPOS L**, MORRIS MI, REDER AT, TORNATORE C, GERSHON A, GERSHON M, LEVIN MJ, BEZUIDENHOUDT M, PUTZKI N.
Varicella-zoster virus infections in patients treated with fingolimod: Risk assessment and consensus recommendations for management
JAMA Neurol 2015; 72(1):31-9. IF: 7.271
5. **BENDFELDT K**, SMIESKOVA R, KOUTSOULERIS N, KLÖPPEL S, SCHMIDT A, WALTER A, HARRISBERGER F, WREGE J, SIMON A, TASCHLER B, NICHOLS T, RIECHER-RÖSSLER A, LANG EU, **RADUE EW**, BORGWARDT S
Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing
Neuroimage Clin 2015; 9:555-63. IF: 1.289
6. BERGER CT, GREIFF V, **MEHLING M**, FRITZ S, MEIER MA, HOENGER G, CONEN A, RECHER M, BATTEGAY M, REDDY ST, HESS C
Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection
Hum Vaccin Immunother. 2015;11(2):391-6. IF: 2.4
7. BERNASCONI R, SMIESKOVA R, SCHMIDT A, HARRISBERGER F, RASCHLE NM, LENZ C, WALTER A, SIMON A, RIECHER-RÖSSLER A, **RADUE EW**, LANG UE, FUSAR-POLI P, BORGWARDT SJ
Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication.
Neuroimage Clin 2015; 8:230-7. IF: 1.289
8. BLÖCHLIGER M, **RÜEGG S**, JICK SS, MEIER CR, BODMER M
Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis
CNS Drugs 2015; 29: 591-603. IF: 5.113
9. BLÖCHLIGER M, CESCHI A, **RÜEGG S**, KUPFERSCHMIDT H, KRAEHENBUEHL S, JICK SS, MEIER CR, BODMER M
Risk of seizures associated with antidepressant use in patients with depressive disorder: follow-up study with a nested case-control analysis using the Clinical Practice Research Datalink
Drug Saf 2015 Dec 9 [Epub ahead of print]. IF: 2.824
10. **BONATI LH**, DOBSON J, FEATHERSTONE RL, EDERLE J, VAN DER WORP HB, DE BORST GJ, MALI WP, BEARD JD, CLEVELAND T, **ENGELTER ST**, **LYRER PA**, FORD GA, DORMAN PJ, BROWN MM, INTERNATIONAL CAROTID STENTING STUDY I
Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial
Lancet. 2015; 385:529-38. IF: 45.217
11. **BONATI LH**, NEDERKOORN PJ
Clinical Perspective of Carotid Plaque Imaging
Neuroimaging Clin N Am. 2016; 26:175-82. IF: 1.527
12. BONATI U, **HAFNER P**, SCHÄDELIN S, SCHMID M, NADUVILEKOOT DEVASIA A, SCHROEDER J, ZUESLI S, POHLMAN U, NEUHAUS C, KLEIN A, **SINNREICH M**, HAAS T, GLOOR M, BIERI O, FISCHMANN A, **FISCHER D**
Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy.
Neuromuscul Disord. 2015; 25(9):679-85 Epub 2015 Jun 4. IF: 2.6
13. BONATI U, SCHMID M, **HAFNER P**, HAAS T, BIERI O, GLOOR M, FISCHMANN A, **FISCHER D**
Longitudinal 2-point dixon muscle magnetic resonance imaging in becker muscular dystrophy
Muscle Nerve. 2015;51(6):918-21. Epub 2015 Mar 31. IF: 2.283
14. BRODERICK JP, BERKHEMER OA, PALESCH YY, DIPPEL DW, FOSTER LD, ROOS YB, VAN DER LUGT A, TOMSICK TA, MAJOIE CB, VAN ZWAM WH, DEMCHUK AM, VAN OOSTENBRUGGE RJ, KHATRI P, LINGSMA HF, HILL MD, ROOZENBEEK B, JAUCH EC, JOVIN TG, YAN B, VON KUMMER R, MOLINA CA, GOYAL M, SCHONEWILLE WJ, MAZIGHI M, **ENGELTER ST**, ANDERSON CS, SPILKER J, CARROZZELLA J, RYCKBORST KJ, JANIS LS, SIMPSON KN
Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data
Stroke. 2015; 46(12):3416-22. IF: 5.723

15. CANTÓ E, TINTORÉ M, VILLAR LM, COSTA C, NURTDINOV R, ÁLVAREZ-CERMEÑO JC, ARRAMBIDE G, REVERTER F, DEISENHAMMER F, HEGEN H, KHADEMI M, OLSSON T, TUMANI H, RODRÍGUEZ-MARTÍN E, PIEHL F, BARTOS A, ZIMOVA D, KOTOUCOVA J, **KUHLE J, KAPPOS L**, GARCÍA-MERINO JA, SÁNCHEZ AJ, SAIZ A, BLANCO Y, HINTZEN R, JAFARI N, BRASSAT D, LAUDA F, ROESLER R, REJDAK K, PAPUC E, DE ANDRÉS C, RAUCH S, KHALIL M, ENZINGER C, GALIMBERTI D, SCARPINI E, TEUNISSEN C, SÁNCHEZ A, ROVIRA A, MONTALBAN X, COMABELLA M
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
Brain 2015; 138(Pt 4):918-31. IF: 9.196
16. CHIU I, GFROERER RI, PIGUET O, BERRES M, MONSCH AU, **SOLLBERGER M**
"Now I see it, now I don't": determining threshold levels of facial emotion recognition for use in patient populations
J Int Neuropsychol Soc. 2015; 21(7):568-72. IF: 2.963
17. COHEN JA, KHATRI B, BARKHOF F, COMI G, HARTUNG HP, MONTALBAN X, PELLETIER J, STITES T, RITTER S, VON ROSENSTIEL P, TOMIC D, **KAPPOS L** on behalf of the TRANSFORMS (trial assessing injectable interferon vs. FTY720 oral in RRMS) study group
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study
J Neurol Neurosurg Psychiatry 2015 Jun 25 [Epub ahead of print] IF: 6.807
18. COMI G, GOLD R, DAHLKE F, SINHA A, VON ROSENSTIEL P, TOMIC D, **KAPPOS L**
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Mult Scler J 2015; 21(6):786-90. IF: 4.822
19. CONSTANTINESCU CS, ASHER A, FRYZE W, KOZUBSKI W, WAGNER F, ARAM J, TANASESCU R, KOROLKIEWICZ RP, DIRNBERGER-HERTWECK M, STEIDL S, **SPRENGER T, RADUE EW**
Phase Ib trial of MOR103, a human antibody to GM-CSF, in patients with multiple sclerosis
Neurol Neuroimmunol Neuroinflamm. 2015; 2(4):e117.
20. DEBETTE S, COMPTER A, LABEYRIE MA, UYTENBOOGAART M, METSO TM, MAJERSIK JJ, GOEGGEL-SIMONETTI B, **ENGELTER ST**, PEZZINI A, BIJLENGA P, SOUTHERLAND AM, NAGGARA O, BEJOT Y, COLE JW, DUCROS A, GIACALONE G, SCHILLING S, REINER P, SARIKAYA H, WELLEWEERD JC, KAPPELLE LJ, DE BORST GJ, **BONATI LH**, JUNG S, THIJS V, MARTIN JJ, BRANDT T, GROND-GINSBACH C, KLOSS M, MIZUTANI T, MINEMATSU K, MESCHIA JF, PEREIRA VM, BERSANO A, TOUZE E, **LYRER PA**, LEYS D, CHABRIAT H, MARKUS HS, WORRALL BB, CHABRIER S, BAUMGARTNER R, STAPF C, TATLISUMAK T, ARNOLD M, BOUSSER MG
Epidemiology, pathophysiology, diagnosis, and management of intracranial artery dissection
Lancet Neurol. 2015;14:640-54. IF: 21.896
21. DEBETTE S, KAMATANI Y, METSO TM, KLOSS M, CHAUHAN G, **ENGELTER ST**, PEZZINI A, THIJS V, MARKUS HS, DICHGANS M, WOLF C, DITTRICH R, TOUZE E, SOUTHERLAND AM, SAMSON Y, ABOUD S, BEJOT Y, CASO V, BERSANO A, GSCHWENDTNER A, SESSA M, COLE J, LAMY C, MEDEIROS E, BERETTA S, **BONATI LH**, GRAU AJ, MICHEL P, MAJERSIK JJ, SHARMA P, KALASHNIKOVA L, NAZAROVA M, DOBRYNINA L, BARTELS E, GUILLON B, VAN DEN DEN HERIK EG, FERNANDEZ-CADENAS I, JOOD K, NALLS MA, DE LEEUW FE, JERN C, CHENG YC, WERNER I, METSO AJ, LICHY C, **LYRER PA**, BRANDT T, BONCORAGLIO GB, WICHMANN HE, GIEGER C, JOHNSON AD, BOTTCHER T, CASTELLANO M, ARVEILER D, IKRAM MA, BRETELER MM, PADOVANI A, MESCHIA JF, KUHLENBAUMER G, ROLFS A, WORRALL BB, INTERNATIONAL STROKE GENETICS C, RINGELSTEIN EB, ZELENKA D, TATLISUMAK T, LATHROP M, LEYS D, GROUP C, AMOUYEL P, DALLONGEVILLE J, CADISP G
Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection
Nat Genet. 2015;47:78-83 IF: 29.352
22. **DÉCARD BF, FLADT J, AXER H, FISCHER D, GRIMM A**
Nerve ultrasound in miller fisher variant of Guillain-Barré syndrome
Muscle Nerve. 2015 Jun 29. [Epub ahead of print] IF: 2.283
23. **DÉCARD BF, GRIMM A, ANDELOVA M**, DEMAN A, BANDERET B, GARCIA M, **FUHR P**
Hepatitis-E virus associated neuralgic amyotrophy with sustained plexus brachialis swelling visualized by high-resolution ultrasound
J Neurol Sci. 2015; 351(1-2):208-10. IF: 2.474
24. **DE MARCHIS GM**, FILIPPI CG, GUO X, PUGIN D, GAFFNEY CD, DANGAYACH NS, SUWATCHARANGKON S, FALO MC, SCHMIDT JM, AGARWAL S, CONNOLLY ES JR., CLAASSEN J, ZHAO B, MAYER SA
Brain injury visible on early MRI after subarachnoid hemorrhage might predict neurological impairment and functional outcome
Neurocrit Care. 2015; 22:74-81 IF: 2.604
25. **DE MARCHIS GM**, PUGIN D, MEYERS E, VELASQUEZ A, SUWATCHARANGKON S, PARK S, FALO MC, AGARWAL S, MAYER SA, SCHMIDT JM, CONNOLLY ES, CLAASSEN J
Seizure burden in subarachnoid hemorrhage: Association with functional outcome and cognitive outcome at 3 months
Neurology 2015 Dec 23. [Epub ahead of print] IF: 8.286
26. DENIER N, SCHMIDT A, GERBER H, VOGEL M, HUBER CG, LANG UE, RIECHER-ROSSLER A, WIESBECK GA, **RADUE EW**, WALTER M, BORGWARDT S
Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment
Hum Brain Mapp 2015; 36(12):5287-300. IF: 5.969
27. **DERFUSS T**, BERGVALL NK, SFIKAS N, TOMIC DL
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
Curr Med Res Opin. 2015; 31(9):1687-91. IF 2.7
28. **DERFUSS T**, CURTIN F, **GUEBELIN C**, BRIDEL C, **RASENACK M**, MATTHEY A, PASQUIER RD, SCHLUEP M, DESMEULES J, LANG AB, PERRON H, FAUCARD R, PORCHET H, HARTUNG HP, **KAPPOS L**, LALIVE PH

A phase IIa randomised clinical study of GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients
Mult Scler J 2015; 21(7):885-93. IF: 4.822

29. **DERFUSS T, CURTIN F, GUEBELIN C, BRIDEL C, RASENACK M, MATTHEY A, DU PASQUIER R, SCHLUEP M, DESMEULES J, LANG AB, PERRON H, FAUCARD R, PORCHET H, HARTUNG HP, KAPPOS L, LALIVE PH**
A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up
J Neuroimmunol 2015; 285:68-70. IF: 2.467
30. **DOIG D, TURNER EL, DOBSON J, FEATHERSTONE RL, DE BORST GJ, STANSBY G, BEARD JD, ENGELTER ST, RICHARDS T, BROWN MM, INVESTIGATORS I**
Risk factors for stroke, myocardial infarction, or death following carotid endarterectomy: Results from the international carotid stenting study
Eur J Vasc Endovasc Surg. 2015; 50(6):688-94. IF: 2.490
31. **EGLI SC, HIRNI DI, TAYLOR KI, BERRES M, REGENITER A, GASS A, MONSCH AU, SOLLBERGER M**
Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample
J Alzheimers Dis. 2015; 44(2):625-33. IF: 4.151
32. **FITZGERALD KC, MUNGER KL, KÖCHERT K, ARNASON BG, COMI G, COOK S, GOODIN DS, FILIPPI M, HARTUNG HP, JEFFERY DR, O'CONNOR P, SUAREZ G, SANDBRINK R, KAPPOS L, POHL C, ASCHERIO A**
Association of Vitamin D levels with Multiple Sclerosis activity and progression in patients receiving Interferon Beta-1b
JAMA Neurol 2015; 72(12): 1458-1465. IF: 7.271
33. **FREEDMAN MS, WOLINSKY JS, TRUFFINET P, COMI G, KAPPOS L, MILLER AE, OLSSON TP, BENAMOR M, CHAMBERS S, O'CONNOR PW FOR THE TERIFLUNOMIDE MULTIPLE SCLEROSIS TRIAL GROUP AND THE MRI ANALYSIS CENTER**
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
Mult Scler J – Exper Transl Clin 2015; (1):1-10
34. **FUHR P, SCHINDLER C**
Clinical neurophysiology in Multiple Sclerosis – from diagnostic tool to biomarker
Clin Neurophysiol. 2015; 126(1):7-9. IF: 3.144
35. **FUHR P, ZIMMERMANN R, GSCHWANDTNER U**
Author response to Sturm W. “Cognitive training in Parkinson disease: Cognition-specific vs nonspecific computer training”
Neurology 2015; 84(1):104.
Neurology 2015; 84(1):104-5. IF: 8.286
36. **GARCIA M, GLOOR M, BIERI O, RADUE EW, LIEB JM, CORDIER D, STIPPICH C**
Imaging of primary brain tumors and metastases with fast quantitative 3-dimensional magnetization transfer
Neuroimage 2015; 25:1007-14. IF: 6.357
37. **GASS A, ROCCA MA, AGOSTA F, CICCARELLI O, CHARD D, VALSASINA P, BROOKS JC, BISCHOF A, EISELE P, KAPPOS L, BARKHOF F, FILIPPI M, MAGNIMS Study Group**
MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis.
Lancet Neurol. 2015; 14(4):443-54. IF: 21.896
38. **GENSICKE H, AHLHELM F, JUNG S, VON HESSLING A, TRAENKA C, GOEGGEL SIMONETTI B, PETERS N, BONATI LH, FISCHER U, BROEG-MORVAY A, SEIFFGE DJ, GRALLA J, STIPPICH C, BAUMGARTNER RW, LYRER PA, ARNOLD M, ENGELTER ST**
New ischaemic brain lesions in cervical artery dissection stratified to antiplatelets or anticoagulants
Eur J Neurol. 2015; 22(5):859-65. IF: 4.055
39. **GENSICKE H, BONATI LH, INVESTIGATORS I-MS**
Reply: Stent type and risk of late cerebral events after carotid artery stenting
J Am Coll Cardiol. 2015; 66:490-1. IF: 16.503
40. **GENSICKE H, VAN DER WORP HB, NEDERKOORN PJ, MACDONALD S, GAINES PA, VAN DER LUGT A, MALI WP, LYRER PA, PETERS N, FEATHERSTONE RL, DE BORST GJ, ENGELTER ST, BROWN MM, BONATI LH, ICSS-MRI SUBSTUDY I**
Ischemic brain lesions after carotid artery stenting increase future cerebrovascular risk
J Am Coll Cardiol. 2015; 65:521-9. IF: 16.503
41. **GIOVANNONI G, GOLD R, FOX RJ, KAPPOS L, KITA M, YANG M, SARDA SP, ZHANG R, VIGLIETTA V, HAVRDOVA E**
Relapses requiring intravenous steroid use and Multiple-Sclerosis-related hospitalizations: Integrated analysis of the delayed-release Dimethyl Fumarate Phase 3 Studies
Clin Ther. 2015; 37(11):2543-51. IF: 2.731
42. **GIOVANNONI G, DE JONG B, DERFUSS T, IZQUIERDO G, MAZIBRADA G, MOLYNEUX P, NICHOLAS R, OVERELL J, ZIEMSEN T, JULIUSSON G**
A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
Mult Scler Relat Disord. 2015; 4(1):83-4. IF 0.884
43. **GLODZIK L, SOLLBERGER M, GASS A, GOKHALE A, RUSINEK H, BABB JS, HIRSCH JG, AMANN M, MONSCH AU, GONEN O**
Global N-Acetylaspartate in normal subjects, mild cognitive impairment and Alzheimer patients
Journal of Alzheimer's Disease 2015; 43(3):939-47 IF: 4.151

44. GOEGGEL SIMONETTI B, MONO ML, HUYNH-DO U, MICHEL P, ODIER C, SZTAJZEL R, **LYRER PA, ENGELTER ST, BONATI LH, GENSICKE H, TRAEENKA C**, TETTENBORN B, WEDER B, FISCHER U, GALIMANIS A, JUNG S, LUEDI R, **DE MARCHIS GM**, WECK A, CEREDA CW, BAUMGARTNER R, BASSETTI CL, MATTLE HP, NEDELTCHEV K, ARNOLD M
Risk factors, aetiology and outcome of ischaemic stroke in young adults: the Swiss Young Stroke Study (SYSS)
J Neurol. 2015;262:2025-32 IF: 3.377
45. GOLD R, PHILLIPS JT, HAVRDOVA E, BAR-OR A, **KAPPOS L**, KIM N, THULLEN T, VALENCIA P, OLIVA L, NOVAS M, LI J, SWEETSER MT, KURUKULASURIYA N, VIGLIETTA V, FOX RJ
Delayed-release Dimethyl Fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience
Neurol Ther. 2015; 4(2):93-104
46. **GRIMM A, DÉCARD BF, ATHANASOPOULOU I, SCHWEIKERT K, SINNREICH M**, AXER H
Nerve ultrasound for differentiation between amyotrophic lateral sclerosis and multifocal motor neuropathy
J Neurol. 2015; 262(4):870-80. IF: 3.4
47. **GRIMM A, DÉCARD BF**, AXER H, **FUHR P**
The Ultrasound Pattern Sum Score - UPSS. A new method to differentiate acute and subacute neuropathies using ultrasound of the peripheral nerves
Clin Neurophysiol. 2015; 126(11):2216-25. IF: 3.097
48. **GRIMM A, DÉCARD BF**, SCHRAMM A, **PRÖBSTE AK, RASENACK M**, AXER H*, **FUHR P*** (* contributed equally)
Ultrasound and electrophysiologic findings in patients with Guillain-Barré syndrome at disease onset and over a period of six months
Clin Neurophysiol. 2015 Jul 21. [Epub ahead of print] IF: 3.097
49. **GRIMM A, RASENACK M, ATHANASOPOULOU IM**, DAMMEIER NM, LIPSKI C, WOLKING S, VITTORE D, **DÉCARD BF**, AXER H
The modified Ultrasound Pattern Sum Score mUPSS as additional diagnostic tool for genetically distinct hereditary neuropathies
J Neurol. 2015 Nov 11. [Epub ahead of print] IF: 3.377
50. **GRIMM A, RASENACK M, ATHANASOPOULOU IM, PETERS N, FUHR P**
Long-term observations in asymmetric immune-mediated neuropathy with vagus hypertrophy using ultrasound of the nerves
J Neurol Sci. 2015; 356(1-2):205-8. IF: 2.474
51. GROND-GINSBACH C, LICHY C, DEBETTE S, LEYS D, PEZZINI A, METSO T, TATLISUMAK T, **GENSICKE H, ENGELTER ST**
Cervical Artery Dissection (CeAD) in physicians
Cerebrovasc Dis. 2015;39:72-4 IF: 3.754
52. HARTUNG HP, **KAPPOS L**, GOODIN DS, O'CONNOR P, FILIPPI M, ARNASON B, COMI G, COOK S, JEFFERY D, PETKAU J, WHITE R, BOGUMIL T, BECKMANN K, STEMPER B, SUAREZ G, SANDBRINK R, POHL C on behalf of the BEYOND study group
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
J Neurol 2015; 262(11):2466-71. IF: 3.377
53. **HATZ F, HARDMEIER M**, BENZ N, EHRENSPERGER M, **GSCHWANDTNER U, RÜEGG S**, SCHINDLER C, MONSCH AU, **FUHR P**
Microstate connectivity alterations in patients with early Alzheimer's disease
Alzheimers Res Ther. 2015; 7(1):78. IF: 3.979
54. **HATZ F, HADMEIER M**, BOUSLEIMAN H, **RÜEGG S**, SCHINDLER C, **FUHR P**
Reliability of fully automated versus visually controlled pre- and post-processing of resting-state EEG
Clin Neurophysiol 2015; 126: 268-74. IF: 3.097
55. HOUGAARD A, AMIN FM, HOFFMANN MB, LARSSON HBW, **MAGON S, SPRENGER T**, ASHINA M
Structural grey matter abnormalities in migraine relate to head pain lateralization, but not aura
Cephalalgia 2015; 35(1):3-9 IF: 4.891
56. HOUGAARD A, AMIN FA, **MAGON S, SPRENGER T**, ROSTRUP E, ASHINA M
No abnormalities of intrinsic brain connectivity during the interictal phase of migraine with aura
Eur J Neurol 2015; 22(4):702-e46. IF: 4.055
57. HUBACHER M, DELUCA J, WEBER P, STEINLIN M, **KAPPOS L**, OPWIS K, PENNER IK
Cognitive rehabilitation of working memory in juvenile Multiple Sclerosis – Effects on cognitive functioning, functional MRI and network related connectivity
Restor Neurol Neuros 2015; 33(5):713-25. IF: 2.490
58. HUPPERTS R, BECKER V, FRIEDRICH J, **GOBBI C**, SALGADO AV, SPERLING B, YOU X
Multiple sclerosis patients treated with intramuscular interferon-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life, and satisfaction
Expert Opin Drug Deliv. 2015; 12(1):15-25. IF 4.116
59. JEFFERY DR, DI CANTOGNO EV, RITTER S, MEIER DP, **RADUE EW**, CAMU W
The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS
J Neurol 2015 Nov 14; [Epub ahead of print] IF: 3.377
60. KAISER A, EPPENBERGER LS, SMIESKOVA R, BORGBWARDT S, KUENZLI E, **RADUE EW**, NITSCH C, **BENDFELDT K**
Age of second language acquisition in multilinguals has an impact on gray matter volume in language-associated brain areas.
Front Psychol 2015; 6:638. IF: 2.6

61. **KAPPOS L, DE STEFANO N, FREEDMAN MS, CREE BAC, RADUE EW, SPRENGER T, SORMANI MP, SMITH T, HÄRING DA, PIANI MEIER D, TOMIC D**
Inclusion of brain volume loss in a revised measure of no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Mult Scler J 2015 Nov 23 [Epub ahead of print] IF: 4.822
62. **KAPPOS L, GIOVANNONI G, GOLD R, PHILLIPS JT, ARNOLD DL, HOTERMANS C, ZHANG A, VIGLIETTA V, FOX RJ for the DEFINE and CONFIRM study investigators**
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
Eur J Neurol 2015; 22(4):664-71. IF: 4.055
63. **KAPPOS L, KUHLE J, MULTANEN J, KREMENCHUTZKY M, VERDUN DI CANTOGNO E, CORNELISSE P, LEHR L, CASSET-SEMANAZ F, ISSARD D, UITDEHAAG BMJ**
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15
J Neurol Neurosurg Psychiatry 2015; 86(11):1202-7 IF: 6.807
64. **KAPPOS L, MEHLING M, ARROYO R, IZQUIERDO G, SELMAJ K, CUROVIC-PERISIC V, KEIL A, BIJARNIA M, SINGH A, VON ROSENSTIEL P**
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
Neurology 2015; 84(9):872-9. IF: 8.286
65. **KAPPOS L, O'CONNOR P, RADUE EW, POLMAN C, HOHLFELD R, SELMAJ K, RITTER S, SCHLOSSHAUER R, VON ROSENSTIEL P, ZHANG-AUBERSON L, FRANCIS G**
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial
Neurology 2015; 84(15):1582-91. IF: 8.286
66. **KAPPOS L, RADUE EW, CHIN P, RITTER S, TOMIC D, LUBLIN F**
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
J Neurol 2015 Dec 8 [Epub ahead of print] IF: 3.377
67. **KAPPOS L, RADUE EW, COMI G, MONTALBAN X, BUTZKUEVEN H, WIENDL H, GIOVANNONI G, HARTUNG HP, DERFUSS T, NAEGELIN Y, SPRENGER T, MUELLER-LENKE N, GRIFFITHS S, VON ROSENSTIEL P, GOTTSCHALK R, ZHANG Y, DAHLKE F, TOMIC D; TOFINGO STUDY GROUP**
Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS
Neurology 2015; 85(1):29-39 IF: 8.286
68. **KAPPOS L, WIENDL H, SELMAJ K, ARNOLD DL, HAVRDOVA E, BOYKO A, KAUFMAN M, ROSE J, GREENBERG S, SWEETSER M, RIESTER K, O'NEILL G, ELKINS J**
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
N Engl J Med 2015; 373(15):1418-28 IF: 55.873
69. KAUFMAN M, CREE BA, DE SÈZE J, FOX RJ, GOLD R, HARTUNG HP, JEFFERY D, **KAPPOS L**, MONTALBÁN X, WEINSTOCK-GUTTMAN B, TICHO B, DUDA P, PACE A, CAMPAGNOLO D.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
J Neurol 2015; 262(2):326-36. IF: 3.377
70. KELLERT L, KLOSS M, PEZZINI A, METSO TM, METSO AJ, DEBETTE S, LEYS D, CASO V, THIJS V, BERSANO A, TOUZE E, TATLISUMAK T, **GENSICKE H, LYRER PA, BOSEL J, ENGELTER ST, GROND-GINSBACH C, CERVICAL ARTERY DISSECTION ISCHAEMIC STROKE PATIENTS STUDY G**
Anemia in young patients with ischaemic stroke
Eur J Neurol. 2015; 22:948-53 IF: 4.055
71. KELLINGHAUS C, LANG N, ROSSETTI AO, **RÜEGG S**, TILZ C, TRINKA E, UNTERBERGER I, UZELAC Z, ROSENOW F
Making SENSE – Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry
BMC Neurol 2015 Nov 10;15:230. IF: 2.040
72. KILLEEN T, JUCKER D, WENT P, MUTHURAJAH V, WOON K, CESNULIS E, **CZAPLINSKI A**
Solitary tumour-like mass lesions of the central nervous system: Primary angiitis of the CNS and inflammatory pseudotumour
Clin Neurol Neurosurg. 2015; 135:34-7.
73. **KUHLE J, DISANTO G, DOBSON R, ADIUTORI R, BIANCHI L, TOPPING J, BESTWICK JP, MEIER UC, MARTA M, COSTA GD, RUNIA T, EVDOSHENKO E, LAZAREVA N, THOUVENOT E, IAFFALDANO P, DIRENZO V, KHADEMI M, PIEHL F, COMABELLA M, SOMBEKKE M, KILLESTEIN J, HEGEN H, RAUCH S, D'ALFONSO S, ALVAREZ-CERMEÑO JC, KLEINOVÁ P, HORÁKOVÁ D, ROESLER R, LAUDA F, LLUFRIU S, AVSAR T, UYGUNOGLU U, ALTINTAS A, SAIP S, MENGE T, RAJDA C, BERGAMASCHI R, MOLL N, KHALIL M, MARIGNIER R, DUJMOVIC I, LARSSON H, MALMESTROM C, SCARPINI E, FENOGLIO C, WERGELAND S, LARONI A, ANNIBALI V, ROMANO S, MARTÍNEZ AD, CARRA A, SALVETTI M, UCCELLI A, TORKILDSEN Ø, MYHR KM, GALIMBERTI D, REJDAK K, LYCKE J, FREDERIKSEN JL, DRULOVIĆ J, CONFAVREUX C, BRASSAT D, ENZINGER C, FUCHS S, BOSCA I, PELLETIER J, PICARD C, COLOMBO E, FRANCIOTTA D, **DERFUSS T, LINDBERG R, YALDIZLI Ö, VÉCSEI L, KIESEIER BC, HARTUNG HP, VILLOSLADA P, SIVA A, SAIZ A, TUMANI H, HAVRDOVÁ E, VILLAR LM, LEONE M, BARIZZONE N, DEISENHAMMER F, TEUNISSEN C, MONTALBAN X, TINTORÉ M, OLSSON T, TROJANO M, LEHMANN S, CASTELNOVO G, LAPIN S, HINTZEN R, KAPPOS L, FURLAN R, MARTINELLI V, COMI G, RAMAGOPALAN SV, GIOVANNONI G**
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
Mult Scler J 2015; 21(8):1013-24. IF: 4.822**
74. **KUHLE J, DISANTO G, LORSCHIEDER J, STITES T, CHEN Y, DAHLKE F, FRANCIS G, SHRINIVASAN A, RADUE EW, GIOVANNONI G, KAPPOS L**

75. **KUHLE J**, GAIOTTINO J, LEPPERT D, PETZOLD A, BESTWICK JP, MALASPINA A, LU CH, DOBSON R, DISANTO G, NORGREN N, NISSIM A, **KAPPOS L**, HURLBERT J, YONG VW, GIOVANNONI G, CASHA S
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
J Neurol Neurosurg Psychiatry 2015; 86(3):273-9. IF: 6.807
76. **KUHLE J**, **HARDMEIER M**, **DISANTO G**, GUGLETA K, ECSEDI M, LIENERT C, AMATO MP, BAUM K, BUTTMANN M, BAYAS A, BRASSAT D, BROCHET B, CONFAVREUX C, EDAN G, FÄRKKILÄ M, FREDRIKSON S, FRONTONI M, D'HOOGHE M, HUTCHINSON M, DE KEYSER J, KIESEIER BC, KÜMPFEL T, RIO J, POLMAN C, ROULLET E, STOLZ C, VASS K, WANDINGER KP, **KAPPOS L**;
European Long-term Follow-up Study Group in Interferon β -1b in Secondary-progressive Multiple Sclerosis
A 10-year follow-up of the European multicenter trial of interferon β -1b in secondary-progressive multiple sclerosis
Mult Scler J 2015 Sep 11 [Epub ahead of print] IF: 4.822
77. LICHY C, METSO A, PEZZINI A, LEYS D, METSO T, **LYRER PA**, DEBETTE S, THIJS V, ABOUD S, KLOSS M, SAMSON Y, CASO V, SESSA M, BERETTA S, LAMY C, MEDEIROS E, BERSANO A, TOUZE E, TATLISUMAK T, GRAU A, BRANDT T, **ENGELTER ST**, GROND-GINSBACH C, CERVICAL ARTERY D, ISCHEMIC STROKE PATIENTS-STUDY G
Predictors of delayed stroke in patients with cervical artery dissection
Int J Stroke. 2015; 10:360-3. IF: 3.833
78. LIU Z, PARDINI M, **YALDIZLI Ö**, SETHI V, MUHLERT N, WHEELER-KINGSHOTT CAM, SAMSON RS, MILLER DH, CHARD DT
Magnetisation transfer ratio measures in normal appearing white matter show periventricular gradient abnormalities in multiple sclerosis
Brain 2015; 138(Pt 5):1239-46. IF: 9.196
79. LIU Z, **YALDIZLI Ö**, PARDINI M, SETHI V, KEARNEY H, MUHLERT N, WHEELER-KINGSHOTT CAM, MILLER DH, CHARD DT
Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis
Mult Scler Relat Disord. 2015; 4(1):52-7. IF: 0.884
80. LU CH, MACDONALD-WALLIS C, GRAY E, PEARCE N, PETZOLD A, NORGREN N, GIOVANNONI G, FRATTA P, SIDLE K, FISH M, ORRELL R, HOWARD R, TALBOT K, GREENSMITH L, **KUHLE J***, TURNER MR*, MALASPINA A* (*contributed equally)
Neurofilament light chain in blood is a prognostic biomarker for amyotrophic lateral sclerosis
Neurology 2015; 84:2247-2257 IF: 8.286
81. LU CH, PETZOLD A, TOPPING J, ALLEN K, MACDONALD-WALLIS C, CLARKE J, PEARCE N, **KUHLE J**, GIOVANNONI G, FRATTA P, SIDLE K, FISH M, ORRELL R, HOWARD R, GREENSMITH L, MALASPINA A
Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
J Neurol Neurosurg Psychiatry 2015;86:565-573 IF: 6.807
82. LUKAS C, KNOL DL, SOMBEKKE MH, BELLENBERG B, HAHN HK, POPESCU V, **WEIER K**, **RADUE EW**, **GASS A**, **KAPPOS L**, **NAEGELIN Y**, UITDEHAAG BM, GEURTS JG, BARKHOF F, VRENKEN H
Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis
J Neurol Neurosurg Psychiatry 2015; 86(4):410-8. IF: 6.807
83. **MAGON S**, MAY A, STANKEWITZ A, GOADSBY PJ, TSO AR, ASHINA M, AMIN FM, SEIFERT CL, CHAKRAVARTY MM, MÜLLER J, **SPRENGER T**
Morphological abnormalities of thalamic subnuclei in migraine: a multi-center MRI study at 3T
J Neurosci 2015; 35(40):13800-6. IF: 6.344
84. MATSUSHITA T, MADIREDDY L, **SPRENGER T**, KHANKHANIAN P, **MAGON S**, **NAEGELIN Y**, CAVERZASI E, **LINDBERG RL**, **KAPPOS L**, HAUSER SL, OKSENBERG JR, HENRY R, PELLETIER D, BARANZINI SE.
Genetic associations with brain cortical thickness in multiple sclerosis
Genes Brain Behav 2015; 14(2):217-27. IF: 3.661
85. **MEHLING M**, BURGNER AV, BRINKMANN V, BANTUG GR, DIMELOE S, HOENGER G, **KAPPOS L**, HESS C
Tissue distribution dynamics of human NK cells inferred from peripheral blood depletion kinetics after Sphingosine-1-phosphate receptor blockade
Scand J Immunol 2015; 82(5):460-6. IF: 1.739
86. **MEHLING M**, FRANK T, ALBAYRAK C, TAY S
Real-time tracking, retrieval and gene expression analysis of migrating human T cells
Lab Chip. 2015; 15(5):1276-83. IF: 6.1
87. MENKE RA, GRAY E, LU CH, **KUHLE J**, TALBOT K, MALASPINA A, TURNER MR
CSF neurofilament light chain reflects corticospinal tract degeneration in ALS
Ann Clin Transl Neurol 2015;2:748-55
88. MEYER A, ZIMMERMANN R, **GSCHWANDTNER U**, **HATZ F**, BOUSLEIMAN H, SCHWARZ N, **FUHR P**
Apathy in Parkinson's disease is related to executive function, gender and age but not to depression
Front Aging Neurosci. 2015; 6:350. IF: 4.0
89. MONTALBAN X, COMI G, ANTEL J, O'CONNOR P, DE VERA A, CREMER M, SFIKAS N, VON ROSENSTIEL P, **KAPPOS L**
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis
J Neurol 2015; 262(12):2627-34. IF: 3.377

90. MORRISON C*, **D'SOUZA M***, H, HUCKVALE K*, DORN J, BURGGRAAFF J, KAMM CP, STEINHEIMER S, KONTSCHIEDER P, VOGEL TH, CRIMINISI A, UITDEHAAG B, DAHLKE F, **KAPPOS L**, SELLEN A (*equal contributing)
Usability and acceptability of the ASSESS MS movement recording tool in Multiple Sclerosis using depth-sensing computer vision
JMIR Human Factors 2015;2(1):e11; IF: 3.428
91. MUNGER KL, FITZGERALD KC, FREEDMAN MS, HARTUNG HP, MILLER DH, MONTALBÁN X, EDAN G, BARKHOF F, SUAREZ G, **RADUE EW**, SANDBRINK R, **KAPPOS L**, POHL C, ASCHERIO A
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT
Neurology 2015; 85(19):1694-701. IF: 8.286
92. PALESCH YY, YEATTS SD, TOMSICK TA, FOSTER LD, DEMCHUK AM, KHATRI P, HILL MD, JAUCH EC, JOVIN TG, YAN B, VON KUMMER R, MOLINA CA, GOYAL M, SCHONEWILLE WJ, MAZIGHI M, **ENGELTER ST**, ANDERSON C, SPILKER J, CARROZZELLA J, RYCKBORST KJ, JANIS LS, SIMPSON A, SIMPSON KN, BRODERICK JP, INTERVENTIONAL MANAGEMENT OF STROKE IIII
Twelve-month clinical and Quality-of-Life outcomes in the interventional management of Stroke IIII Trial
Stroke 2015;46:1321-7 IF: 5.723
93. **PAPADOPOULOU A**, AHLHELM FJ, **LYRER PA**, **KUHLE J**
Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy
Acta Neurol Belg 2015;115:445-7. IF: 0.894
94. PAPINUTTO N, **SCHLAEGER R**, PANARA V, ZHU AH, CAVERZASI E, STERN WA, HAUSER SL, HENRY RG
Age, gender and normalization covariates for spinal cord gray matter and total cross-sectional areas at cervical and thoracic levels: A 2D phase sensitive inversion recovery imaging study
PLoS One. 2015; 10(3):e0118576. IF: 3.234
95. PAPINUTTO N, **SCHLAEGER R**, PANARA V, CAVERZASI E, AHN S, JOHNSON KJ, ZHU AH, STERN WA, LAUB G, HAUSER SL, HENRY RG
2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times
J Magn Reson Imaging 2015; 42(3):698-708. IF: 3.21
96. PARDINI M, CORDANO C, GUIDA S, GRAFMAN J, KRUEGER F, SASSOS D, MASSUCCO D, ABATE L, **YALDIZLI Ö**, SERRATI C, AMORE M, MATTEI C, COCITO L, EMBERTI GIALLORETI L
Prevalence and cognitive underpinnings of isolated apathy in young healthy subjects
J Affect Disord. 2015; 189:272-275. IF: 3.383
97. PARDINI M, **YALDIZLI Ö**, SETHI V, MUHLERT N, LIU Z, SAMSON RS, ALTMANN DR, RON MA, WHEELER-KINGSHOTT CAM, MILLER DH, CHARD DT
Motor network efficiency and disability in multiple sclerosis
Neurology 2015; 85(13):1115-22. IF: 8.286
98. PETERSEN JA, KUNTZER T, **FISCHER D**, VON DER HAGEN M, HUEBNER A, KANA V, LOBRINUS JA, KRESS W, RUSHING EJ, **SINNREICH M**, JUNG HH
Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects
BMC Neurol. 2015;15(1):182. IF: 2
99. **PRÖBSTEL AK**, RUDOLF G, DORNMAIR K, COLLONGUES N, CHANSON JB, **SANDERSON NS**, **LINDBERG RL**, **KAPPOS L**, DE SEZE J, **DERFUSS T**
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
J Neuroinflammation 2015; 12(1):46. IF: 5.408
100. QUAST I, KELLER CW, MAURER MA, GIDDENS JP, TACKENBERG B, WANG LX, MÜNZ C, NIMMERJAHN F, DALAKAS MC, **LÜNEMANN JD**
Sialylation of IgG Fc-domain impairs complement-dependent cytotoxicity
J Clin Invest. 2015; 125(11):4160-70. IF: 13.262
101. QUAST I, CUENI F, NIMMERJAHN F, TACKENBERG B, **LÜNEMANN JD**
Deregulated Fcγ receptor expression in patients with CIDP
Neurol Neuroimmunol Neuroinflamm. 2015; 2(5):e148
102. **RADUE EW**, BARKHOF F, **KAPPOS L***, **SPRENGER T**, HÄRING DA, DE VERA A, VON ROSENSTIEL P, BRIGHT JR, FRANCIS G, COHEN JA (*corresponding author)
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Neurology 2015; 84(8):784-93. IF: 8.286
103. RAMSEIER SP, ROTH S, **CZAPLINSKI A**
A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.
BMC Pharmacol Toxicol. 2015; 16:7 IF: 1.840
104. RAMYEAD A, STUDERUS E, KOMETER M, HEITZ U, **GSCHWANDTNER U**, **FUHR P**, RIECHER-RÖSSLER A
Aberrant current source-density and lagged phase synchronization of neural oscillations as markers for emerging psychosis
Schizophr Bull. 2015, 41: 919-929. IF: 8.450
105. RAMYEAD A, STUDERUS E, KOMETER M, UTTINGER M, **GSCHWANDTNER U**, **FUHR P**, RIECHER-RÖSSLER A
Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients.
World J Biol Psychiatry 2015 Oct 9:1-11 [Epub ahead of print] IF: 4.183

106. REINHARD M, MUNZ M, VON KANNEN AL, GRIESSER-LEUTE HJ, DITTRICH R, **ENGELTER ST**
Risk of recurrent cervical artery dissection during pregnancy, childbirth and puerperium
Eur J Neurol. 2015;22:736-9 IF: 4.055
107. ROCCA M, PRAVATÀ E, VALSASINA P, RADAELLI M, COLOMBO B, VACCHI L, **GOBBI C**, COMI G, FALINI A, FILIPPI M
Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression
Human Brain Mapping 2015; 36(12):5051-63. IF 5.969
108. ROSSEL T, ZEKERIDOU A, OCHSNER F, **RENAUD S.**
Aquaporin-4-positive myelitis associated with Sjögren syndrome and colonic adenocarcinoma.
Neurol Neuroimmunol Neuroinflamm. 2015; 2(3):e103
109. **SCHLAEGER R, HARDMEIER M, D'SOUZA M**, GRIZE L, SCHINDLER C, **KAPPOS L, FUHR P**
Monitoring Multiple Sclerosis by Multimodal Evoked Potentials: numerically versus ordinally scaled scoring systems
Clinical Neurophysiology 2015 Dec 10 [Epub ahead of print] IF: 3.097
110. **SCHLAEGER R**, PAPINUTTO N, ZHU AH, LOBACH IV, BEVAN CJ, BUCCI M, CASTELLANO A, GELFAND JM, GRAVES JS, GREEN AJ, JORDAN KM, KESHAVAN A, PANARA V, STERN WA, VON BÜDINGEN HC, WAUBANT E, GOODIN DS, CREE BA, HAUSER SL, HENRY RG
Association between thoracic spinal cord gray matter atrophy and disability in Multiple Sclerosis
JAMA Neurol. 2015; 72(8):897-904. IF: 7.348
111. SCHMIDT A, DENIER N, **MAGON S, RADUE EW**, HUBER CG, RIECHER-ROSSLER A, WIESBECK GA, LANG UE, BORGWARDT S, WALTER M
Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution.
Transl Psychiatry 2015; 5:e533. IF: 4.36
112. SEIFERT CL, **MAGON S, SPRENGER T**, LANG UE, DENIER N, SCHMIDT A, **RADUE EW**, BORGWARDT S, WALTER M
Reduced volume of the nucleus accumbens in heroin addiction
Eur Arch Psychiatry Clin Neurosci 2015;265(8):637-45. IF: 3.525
113. **SEIFFGE DJ**, HOOFF RJ, NOLTE CH, BEJOT Y, TURC G, IKENBERG B, BERGE E, PERSIKE M, DEQUATRE-PONCHELLE N, STRBIAN D, PFEILSCHIFTER W, ZINI A, TVEITEN A, NAESS H, MICHEL P, SZTAJZEL R, LUFT A, **GENSICKE H, TRAENKA C, HERT L**, SCHEITZ JF, **DE MARCHIS GM, BONATI LH, PETERS N**, CHARIDIMOU A, WERRING DJ, PALM F, REINHARD M, NIESEN WD, NAGAO T, PEZZINI A, CASO V, NEDERKOORN PJ, KÄGE G, VON HESSLING A, PADJEN V, CORDONNIER C, ERDUR H, **LYRER PA**, BROUNS R, STEINER T, TATLISUMAK T, **ENGELTER ST**, NOACISP Study Group
Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome
Circulation 2015;132(13):1261-9 IF: 15.073
114. SKACHOKOVA Z, SPRENGER F, BREU K, ABRAMOWSKI D, CLAVAGUERA F, HENCH J, STAUFENBIEL M, TOLNAY M, **WINKLER DT**
Amyloid- β in the cerebrospinal fluid of APP transgenic mice does not show prion-like properties
Curr Alzheimer Res. 2015;12(9):886-91. IF: 3.889
115. SORMANI MP, DE STEFANO N, FRANCIS G, **SPRENGER T**, CHIN P, **RADUE EW, KAPPOS L**
Fingolimod effect on brain volume loss independently contributes to its effect on disability
Mult Scler J 2015; 21(7):916-24. IF: 4.822
116. SPELMAN T, KALINCIK T, ZHANG A, PELLEGRINI F, WIENDL H, **KAPPOS L**, TSVETKOVA L, BELACHEW S, HYDE R, VERHEUL F, GRAND-MAISON F, IZQUIERDO G, GRAMMOND P, DUQUETTE P, LUGARESI A, LECHNER-SCOTT J, OREJA-GUEVARA C, HUPPERTS R, PETERSEN T, BARNETT M, TROJANO M, BUTZKUEVEN H on behalf of the MSBASE investigators and the TOP investigators
Comparative efficacy of switching to natalizumab in active relapsing multiple sclerosis
Ann Clin Transl Neurol 2015; 2(4):373-87
117. SUTTER R, KAPLAN PW, MARSCH S, HAMMEL EM, **RÜEGG S**, ZIAI W
Early prediction of refractory status epilepticus. An international two-center study
Eur J Neurol 2015; 22: 79-85. IF: 4.055
118. SUTTER R, KAPLAN PW, VALENÇA M, **DE MARCHIS GM**
EEG for diagnosis and prognosis of acute nonhypoxic encephalopathy: history and current evidence
J Clin Neurophysiol. 2015; 32(6):456-64. IF: 1.429
119. SUTTER R, **RÜEGG S**, TSCHUDIN-SUTTER S
Seizures as adverse events of antibiotic drugs: a systematic review
Neurology 2015; 85: 1332-41. IF: 8.286
120. SUTTER R, VALENCA M, TSCHUDIN-SUTTER S, **RÜEGG S**, MARSCH S
Procalcitonin and mortality in status epilepticus: an observational study
Crit Care 2015;19:361. IF: 4.476
121. TOMSICK TA, YEATTS SD, LIEBESKIND DS, CARROZZELLA J, FOSTER L, GOYAL M, VON KUMMER R, HILL MD, DEMCHUK AM, JOVIN T, YAN B, ZAIDAT OO, SCHONEWILLE W, **ENGELTER S**, MARTIN R, KHATRI P, SPILKER J, PALESCH YY, BRODERICK JP, INVESTIGATORS II
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions
J Neurointerv Surg. 2015;7:795-802 IF: 2.774

122. **TRAENKA C, DISANTO G, SEIFFGE DJ, GENSICKE H, HERT L, GROND-GINSBACH C, PETERS N, REGENITER A, KLOSS M, DE MARCHIS GM, BONATI LH, LYRER PA, KUHLE J*, ENGELTER ST*** (* contributed equally)
Serum neurofilament light chain levels are associated with clinical characteristics and outcome in patients with cervical artery dissection
Cerebrovasc Dis. 2015;40(5-6):222-227 IF: 3.754
123. VANACKER P, HELDNER MR, **SEIFFGE JD**, MUELLER H, ESKANDARI A, **TRAENKA C**, NTAIOS G, MOSIMANN PJ, SZTAJZEL R, MENDES PEREIRA V, CRAS P, **ENGELTER ST, LYRER PA**, FISCHER U, LAMBROU D, ARNOLD M, MICHEL P
ASTRAL-R score predicts non-recanalisation after intravenous thrombolysis in acute ischaemic stroke
Thromb Haemost. 2015; 113:1121-6. IF: 4.984
124. VON HESSLING A, **PETERS N**, STIPPICH C
Reperfusion eines inzidentellen Aneurysmas bei mechanischer Schlaganfallbehandlung mit "Stentretreiver"
Fortschr Röntgenstr 2015; 187(10):936-937 IF: 1.402
125. WARRENDER-SPARKES M, SPELMAN T, IZQUIERDO G, TROJANO M, LUGARESI A, GRAND'MAISON F, HAVRDOVA E, HORAKOVA D, BOZ C, OREJA-GUEVARA C, ALROUGHANI R, IULIANO G, DUQUETTE P, GIRARD M, TERZI M, HUPPERTS R, GRAMMOND P, PETERSEN T, FERNANDEZ-BOLAÑOS R, FIOL M, PUCCI E, LECHNER-SCOTT J, VERHEUL F, CRISTIANO E, VAN PESCH V, PETKOVSKA-BOSKOVA T, MOORE F, KISTER I, BERGAMASCHI R, SALADINO ML, SLEE M, BARNETT M, AMATO MP, SHAW C, SHUEY N, YOUNG C, GRAY O, **KAPPOS L**, BUTZKUEVEN H, KALINCIK T, JOKUBAITIS V; MSBASE STUDY GROUP
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Mult Scler J 2015 Jul 21 [Epub ahead of print] IF: 4.822
126. **WEIER K**, ESHAGHI A, **MAGON S, ANDELOVA M, RADUE EW, KAPPOS L**, AZIMI AR, SAHRAIAN MA, **SPRENGER T**
The role of cerebellar abnormalities in neuromyelitis optica – a comparison to multiple sclerosis and healthy controls
Mult Scler J 2015; 21(6):757-66. IF: 4.822
127. **WEIER K**, FONOV V, AUBERT-BROCHE B, ARNOLD LD, BANWELL B, COLLINS DL
Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease
Mult Scler J 2015 Nov 9 [Epub ahead of print] IF: 4.822
128. **WEIER K**, TILL C, FONOV V, YEH A, ARNOLD LD, BANWELL B, COLLINS DL
Contribution of the cerebellum to cognitive function in pediatric multiple sclerosis
Mult Scler J 2015 Jul 22. [Epub ahead of print] IF: 4.822
129. WEYDT P, OECKL P, HUSS A, MÜLLER K, VOLK AE, **KUHLE J**, KNEHR A, ANDERSEN PM, PRUDLO J, STEINACKER P, WEISHAUP T, JH, LUDOLPH AC, OTTO M
Neurofilaments levels as biomarkers in asymptomatic and symptomatic familial ALS
Ann Neurol 2015 Nov 3; [Epub ahead of print] IF: 9.977
130. **WIKTOROWICZ T, KINTER J, KOBUE K, CAMPBELL KP, SINNREICH M**
Genetic characterization and improved genotyping of the dysferlin-deficient mouse strain *Dysf* (tm1Kcam)
Skelet Muscle 2015; 5:32. IF: 5.4
131. WUHRER M, SELMAN MH, MC DONNELL LA, KUEMPFFEL T, **DERFUSS T**, KHADEMI M, OLSSON T, HOHLFELD R, MEINL E, KRUMBHOLZ M
Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid
J Neuroinflammation 2015; 12(1):235. IF 4.9
132. **YALDIZLI Ö**, PARDINI M, SETHI V, MUHLERT N, LIU Z, TOZER DJ, SAMSON RS, WHEELER-KINGSHOTT CAM, YOUSRY TA, MILLER DH, CHARD DT
Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study
Mult Scler J 2015 May 26 [Epub ahead of print] IF: 4.822
133. **YALDIZLI Ö**, PENNER IK, YONEKAWA T, **NAEGELIN Y, KUHLE J**, PARDINI M, CHARD D, STIPPICH C, KIRA J, **BENDFELDT K, AMANN M, RADUE EW, KAPPOS L, SPRENGER T**
The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis
European Journal of Neurology 2015 Nov 19 [Epub ahead of print] IF: 4.055
134. ZANINI C, MAINO P, MÖLLER JC, **GOBBI C**, RAIMONDI M, RUBINELLI S
Enhancing clinical decisions about care through a pre-consultation sheet that captures patients' views on their health conditions and treatments: A qualitative study in the field of chronic pain
Patient Education and Counseling 2015 Dec 3 [Epub ahead of print] IF 2.199
135. ZECCA C, DISANTO G, SORMANI MP, RICCITELLI GC, CIANFONI A, DELGRANDE F, PRAVATÀ E, **GOBBI C**
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis
Mult Scler J 2015 Oct 12 [Epub ahead of print] IF 4.822
136. ZECCA C, HELDNER MR, KAMM CP, RICCITELLI GC, DISANTO G, CAPORRO M, CIANFONI A, PRAVATÀ E, **GOBBI C**
Natalizumab in spinal multiple sclerosis in a daily clinical setting
Expert Opin Biol Ther. 2015; 15(5):633-40. IF 3.653
137. ZECCA C, MAINETTI C, BLUM R, **GOBBI C**
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection - a case report
BMC Neurology 2015; 15:249. IF 2.04

138. ZECCA C, PANICARI L, DISANTO G, MAINO P, SINGH A, DIGESU GA, **GOBBI C**
Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis
International Urogynecology Journal 2015 Aug 6 [Epub ahead of print] IF 1.961
139. **ZIMMERMANN R, GSCHWANDTNER U, HATZ F, SCHINDLER C, BOUSLEIMAN H, AHMED S, HARDMEIER M, MEYER A, CALABRESE P, FUHR P**
Correlation of EEG slowing with cognitive domains in nondemented patients with Parkinson's disease
Dement Geriatr Cogn Disord. 2015; 39:207-14. IF: 3.547
140. **ZIMMERMANN M, SANDERSON NS, RASENACK M, LALIVE PH, LANG AB, CURTIN F, LINDBERG RL, KAPPOS L, DERFUSS T**
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
Neurol Neuroimmunol Neuroinflamm 2015; 2(5):e144

B - BUCHBEITRÄGE, ÜBERSICHTSARBEITEN, EDITORIALS & REVIEWS

(Alphabetisch nach Erstautor sortiert)

1. **ANDELOVA M, BORSOOK D, SPRENGER T**
Imaging of migraine
In: Pathophysiology of Headaches, 1st edition, edited by Ashina M, Geppetti P. Springer International Publishing, Cham, Switzerland, 2015; p. 117-136.
2. BLOCH C, SUTER B, FISCHMANN A, **GENSICKE H, RÜEGG S, WEISSER M**
Only a touch of the flu? The simultaneous manifestation of acute necrotizing encephalopathy in two consanguineous patients
Open Forum Infect Dis 2015; 2(2):ofv013.
3. **BONATI LH**
Stenting or endarterectomy for patients with symptomatic carotid stenosis
Neurol Clin. 2015;33:459-74. IF: 1.395
4. COLLINS C, IVRY B, BOWEN JD, CHENG EM, DOBSON R, GOODIN DS, LECHNER-SCOTT J, **KAPPOS L, GALEA I.**
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools
Mult Scler J 2015 Nov 12. [Epub ahead of print] IF: 4.822
5. **DIEBOLD M, DERFUSS T**
Oral therapies for relapsing-remitting multiple sclerosis
Swiss archives of neurology and psychiatry; 2015; 166(5):170–175.
6. **ENGELTER ST, TRAEENKA C, VON HESSLING A, LYRER PA**
Diagnosis and treatment of cervical artery dissection. In: W. POWERS, ed. Cerebrovascular Diseases: Controversies and Challenges
Neurol Clin. 2015; (33): 421-41. IF: 1.395
7. ENZINGER C, BARKHOF F, CICCARELLI O, FILIPPI M, **KAPPOS L, ROCCA M, ROPELE S, ROVIRA A, SCHNEIDER T, DE STEFANO N, VRENKEN H, WHEELER-KINGSHOTT C, WUERFEL J, FAZEKAS F, MAGNIMS study group**
Nonconventional MRI and microstructural cerebral changes in multiple sclerosis
Nat Rev Neurol 2015; 11(12):676-86. IF: 15.358
8. FREILINGER T, **PETERS N**
Migräne und Schlaganfall – eine komplexe wechselseitige Beziehung
JATROS Neurologie & Psychiatrie, 15(6) 32-36
9. GRANZIERA C, **WEIER K, SPRENGER T**
MRI in Clinical Management of Multiple Sclerosis
In: A. Toga et al. (eds.) Brain Mapping – An Encyclopedic Reference (Vol. 3): Introduction to Clinical Brain Mapping. ISBN: 978-0-12-397316-0, Publisher: Academic Press, Elsevier London, 2015.
10. GRETENER SB, BIERI T, CANOVA CR, ENGELBERGER RP, KUPFER S, **LYRER PA, MEUWLY JY, STAUB D, THALHAMMER C**
Point-of-Care-Sonografie: Let's keep it simple!
Praxis 2015; 104:1033-5.
11. HUBACHER M, **KAPPOS L, WEIER K, STÖCKLIN M, OPWIS K, PENNER IK**
Case-based fMRI analysis after cognitive rehabilitation in MS: A novel approach
Front Neurol. 2015; 6:78.
12. **KAPPOS L, D'SOUZA M, LECHNER-SCOTT J, LIENERT C**
On the origin of Neurostatus
Mult Scler Relat Disord. 2015; 4(3):182-5. IF: 0.884
13. **KAPPOS L, FAZEKAS F**
2015 Multiple Sclerosis Experts Summit. Foreword.
Neurodegener Dis Manag. 2015; 5(6 Suppl): 1-2.

14. **KAPPOS L, FAZEKAS F**
What is new in MS spasticity research? 2015 Multiple Sclerosis Experts Summit. Poster session highlights. *Neurodegener Dis Manag.* 2015; 5(6 Suppl): 27-30
15. **LÜNEMANN JD, NIMMERJAHN F, DALAKAS MC**
Intravenous Immunoglobulin in Neurology: Mechanisms of Action and Clinical Efficacy
Nat Rev Neurol. 2015; 11(2):80-9 IF: 15.358
16. **LYRER PA, MICHEL P**
Akuttherapie des ischämischen Hirnschlags
Cardiovasc. 2015;5:29-34
17. MANIYAR FH, **SPRENGER T**, MONTEITH T, SCHANKIN C, GOADSBY PJ
The premonitory phase of migraine – what can we learn from it?
Headache 2015; 55(5):609-20. IF: 3.189
18. MESSELKEN D, CROUSE J, **WINKLER DT**
When childhood ends: Estimating the age of young people
BMJ 2015; 351: h6699 IF: 17.4
19. **PAPADOPOULOU A, KAPPOS L, SPRENGER T**
Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
Expert Opin Drug Saf. 2015; 14(5):749-59. IF: 2.911
20. PEZOLD S, FUNDANA K, **AMANN M, ANDELOVA M, PFISTER A, SPRENGER T, CATTIN PC**
Automatic segmentation of the spinal cord using continuous max flow with cross-sectional similarity prior and tubularity features
In: *Recent Advances in Computational Methods and Clinical Applications for Spine Imaging.* Yao J., Glocker B., Klinder T., Li S. (Eds.), Springer Verlag, Heidelberg 2015, Pages 107-118. ISBN 978-3-319-14148-0.
21. **PRÖBSTEL AK, SANDERSON NSR, DERFUSS T**
B cells and autoantibodies in multiple sclerosis
Int J Mol Sci. 2015; 16(7):16576-92 IF: 2.862
22. **RENAUD S.**
Polyneuropathien – ein Update
Schweiz Med Forum 2015; (25):600-603
23. ROVIRA A, WATTJES M, TINTORE M, TUR C, YOUSRY T, SORMANI M, DE STEFANO N, FILIPPI M, AUGER C, ROCCA M, BARKHOF F, FAZEKAS F, **KAPPOS L**, POLMAN C, MILLER D, MONTALBAN X, MAGNIMS STUDY GROUP
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis. Clinical implementation in the diagnostic process.
Nat Rev Neurol 2015; 11(8):471-82. IF: 15.358
24. **RÜEGG S**
Wenn Epilepsie die (Auto)mobilität einschränkt
Praxis 2015; 104: 1171.
25. **RÜEGG S, SCHMUTZ M, FUHR P**
Basel contributions to electroencephalography and epileptology
Epileptologie 2015; 32: 31-8.
26. **SINNREICH M**
Muscle pain: what should you think?
Rev Med Suisse 2015; 11(459):319-20.
27. **SPRENGER T, GROSS E**
Migränetherapie-Update: Auf dem Weg zu neuen Applikationswegen und neuen Therapieprinzipien
Hausarzt Praxis 2015;10:10-13.
28. STEINER I, **RÜEGG S**
Another autoimmune encephalitis? – Not yet
Neurology 2015; 84: 1192-3. IF: 8.286
29. TRABOULSEE A, SIMON JH, STONE L, FISHER E, JONES DE, MALHOTRA A, NEWSOME SD, OH J, REICH DS, RICHERT N, RAMMOHAN K, KHAN O, **RADUE EW**, FORD C, HALPER J, LI D
Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of Multiple Sclerosis
AJNR Am J Neuroradiol 2015 Nov 12; [Epub ahead of print] IF: 3.589
30. **WEIER K**
Kurz & Bündig: Hirnvolumenbestimmung als valider Surrogatmarker
Schweizer Zeitschrift für Psychiatrie und Neurologie 2015; 2:31.
31. **WEIER K, BANWELL B, CERASA A, COLLINS DL, DOGONOWSKI AM, LASSMANN H, QUATTRONE A, SAHRAIAN MA, SIEBNER HR, SPRENGER T**
The role of the cerebellum in multiple sclerosis
Cerebellum 2015; 14(3):364-74. IF: 2.7

32. ZIEMSEN T, **DERFUSS T**, DE STEFANO N, GIOVANNONI G, PALAVRA F, TOMIC D, VOLLMER T, SCHIPPLING S.
Optimizing treatment success in multiple sclerosis
J Neurol. 2015 Dec 24; [Epub ahead of print] IF 3.4
33. **ZIMMER A**, BLÄUER C, COSLOVSKY M, **KAPPOS L**, **DERFUSS T**
Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction
Mult Scler Relat Disord 2015; 4(5):444-50. IF: 0.884